ITMIG2025 – Presentations

PROGRAM

Day 1

Session 1. TNM Staging Session

1. What we learned from the 9th edition of theTNM and what we expect to learn from the 10th edition, Enrico Ruffini (Torino, Italy),
2. Nodal dissection: What should surgeons do? Joshua Sonett (New York, USA),
3. The ITMIG-IASLC nodal map, Edith Marom (Tel Aviv, Israel),

Session 2. Recent ITMIG Milestones

1. ITMIG Standards and Definitions, Wentao Fang (Shanghai, China),
2. ITMIG Pathology Guidelines, Anja Roden (Rochester, USA),
3. ITMIG Survey on Clinical and Pathology Practice of the Diagnosis and Treatment of Thymic Epithelial Tumors, Malgorzata Szolkowska (Warsaw Poland),
4. ITMIG Postoperative Radiation Therapy (PORT) project, Frank Detterbeck, (New Haven, USA),

Session 3. Oral Abstract Session 1

1. Machine Learning Models from FDG PET/CT for Predicting Recurrence in Thymomas, Angelo Castello (Milan, Italy),
2. MIST: A Weakly Supervised Deep Learning System for Multicenter Diagnosis of Mediastinal Tumors, Xiaofeng Jiang (Chengdu, China),
3. Central pathology review of thymic tumors: updated analysis of diagnostic concordance in the French RYTHMIC cohort, Álvaro Gutiérrez (Villejuif, France),
4. Weakly Supervised AI-Based Subtyping of Thymic Epithelial Tumors Using H&E Whole Slide Images, Anna Salut Esteve Domínguez (Rotterdam, the Netherlands),
5. FGFR1 amplification in thymic epithelial tumors (TET): A study from 48 cases, Véronique Hofman (Nice, France),
6. Thymic Cancer in France: A Comprehensive Analysis of Incidence Based on French National Healthcare Data, Álvaro Gutiérrez (Villejuif, France).

Session 4. ITMIG-TYME Joint Session

1. Italian network TYME – Aims and Accomplishments, Giulia Galli (Pavia, Italy),
2. TETs Italian Registry – Aims and Accomplishments, Annalisa Trama (Milan, Italy),
3. ITMIG collaboration with national networks and future directions, Nicolas Girard (Paris, France),

Session 5. Bilateral Robotic Thymectomy in Rheumatoid Arthritis: A Multidisciplinary Approach to Complex Surgery.

1. CASE PRESENTATION: Davide Tosi (Milan, Italy),
2. Radiology: Maria Carmela Andrisani (Milan, Italy),
3. Pathology: Giorgio Croci (Milan, Italy),
4. Pulmonology: Antonella Arcadu (Milan, Italy),

Session 6. Management of Recurrent and Re-recurrent Disease

1. CASE PRESENTATION: Giuseppe Calabrese (Rome, Italy),
2. Recurrence and primary TETs: Is it the same disease? Marco Chiappetta (Catanzaro, Italy),
3. Innovative therapies in recurrences of thymic tumors, Christopher Nabel (Boston, USA),
4. The ITMIG recurrence classification: validation and possible updates, Filippo Lococo (Rome, Italy),

Session 7. Anti-angiogenesis, Immunotherapy and Novel Therapies in Thymic Carcinoma

1. The immunotherapy landscape: from clinical trials to clinical practice, Margaret Ottaviano (Naples, Italy),
2. Anti-angiogenics and combinations, Sukhmani K. Padda, Fox (Philadelphia, USA),
3. New treatment strategies: Antibody Drug Conjugates and bispecific Antibody Drug Conjugates, Chul Kim (Washington, USA),
4. Platinum based chemotherapy: still the best option? Martina Imbimbo (Bellinzona, Switzerland),

Session 8. Neoadjuvant therapies: When, how and why

1. What do surgeons need to know from imaging in advanced thymic epithelial tumors? Katarzyna Blasinska (Warsaw, Poland),
2. Potential neoadjuvant use of immunotherapy and targeted therapy in 2025, Magdalena Knetki-Wróblewska, (Warsaw, Poland),
3. Surgical challenges after neoadjuvant therapy, Andrea Billè (London, UK),
4. How to assess pathologic response after neoadjuvant therapy, Andre Moreira, (New York, USA),

Session 9. Nuclear Medicine and Interventional Radiology in TETs – a tailored approach

1. Prognostic value and role of FDG-PET-CT: Initial staging and after therapy, Luca Urso (Ferrara, Italy),
2. Beyond FDG, Angelo Castello (Milan, Italy),
3. Percutaneous ablation therapy in isolated or multiple extra-mediastinal thymic epithelial lesions: is it worthwhile? Giampaolo Carrafiello (Milan, Italy),
4. How to manage difficult cases? An intrapleural recurrence case, Dirk Van Raemdonck, (Leuven, Belgium),

DAY 2

Session 1. Updates on Myasthenia Gravis and Thymic Diseases

1. Perioperative management in patients with myasthenia gravis, Maria Isabel Leite (Oxford, UK),
2. Neurological outcome of thymectomy in patients with myasthenia gravis, Florit Marcuse (Maashricht, The Nederlands),
3. The current and future treatment landscape for myasthenia gravis, Carlo Antozzi (Milan, Italy),

Session 2. Oral Abstract Session 2

1. Autoreactome Analysis Reveals Novel Autoantibodies in Thymoma-Associated Myasthenia Gravis, Linda Kusner (Washington, USA),
2. Towards Understanding Mechanisms of Thymectomy Benefit for Myasthenia Gravis, Henry Kaminski (Washington, USA),
3. Prognostic Nutritional Index and Neutrophil-to-Lymphocyte Ratio Composite Score Predicts Survival in Surgically Resected Thymic Epithelial Tumors: A Retrospective Single Centre Cohort Study, Ke Ma (Chengdu City, China),
4. Clinicopathological and histological features of the thymic hyperplasia combined with Sjögren’s syndrome: an open-label, single-arm observational study, Peng Zhang (Tianjin, China),
5. Surgical Management of TNM Stage IVA Thymoma and Thymic Carcinoma: the network TYME experience [4TYMEs], Riccardo Orlandi (Milan, Italy),
6. Global patterns and trends in thymic epithelial tumors incidence: worldwide healthcare disparity on detection, Bincheng Jiang (Shanghai, China),

Session 3. Surgery session: When and How Surgeons Face Thymomas

1. Mortality risk and cause of death associated with removal of the adult thymus: analysis of the US thymoma population, Benjamin Resio (New Haven, USA),
2. Minimally invasive and hybrid approaches for large tumors, Zhang Yi (Beijing, China),
3. Open surgery: sternotomy, thoracotomy and clamshell incision, Dirk Van Raemdonck (Leuven, Belgium),
4. The approach to phrenic nerve involvement in patients with and without myasthenia gravis, Joshua Sonett (new York, USA),

Session 5. ITMIG Committees and Working Groups Updates

Thymic Carcinoma and Mediastinal Working Groups, Anja Roden (Rochester, USA), 15 min
Education Committee and Mediastinum Collaboration Working Group, Wentao Fang (Shanghai, China), 15 min
Database Committee, Nicolas Girard (Paris, France), 10 min
Biology Working Group, Thierry Molina (Paris, France), 10 min
Artificial Intelligence Working Group, Jan von der Thüsen (Rotterdam, The Netherlands), 10 min
Communication Committee, Chul Kim (Washington, USA), 10 min

Session 6. Multidisciplinary Considerations in Radiotherapy Management and Advances in Radiation Oncology for Thymic Malignancies

1. Surgery considerations for or against postoperative radiation therapy, James Huang (New York, USA) , 12 min
2. Pathology findings important in the decision making of postoperative radiation therapy, Thierry Molina (Paris, France), 12 min
3. Radiation therapy: decision making, outcomes, and modalities, Florence Keane (Boston, USA), 12 min
4. Radiation therapy: post-treatment care and management, Simona Castiglioni (Milan, Italy), 12 min

Session 7. TUMOR BOARD

1. CASE 1: (Myasthenia gravis and advanced disease), PRESENTER: Pietro Bertoglio (Bologna, Italy)
2. CASE 2: (Management issues in a frail patient), PRESENTER: Erica Pietroluongo (Naples, Italy)
3. CASE 3: (Advanced pleural disease), PRESENTER: Stylianos Korasidis (Pisa, Italy)

ABSTRACTS ACCEPTED FOR ITMIG2025